Lung Cancer Alchemist A151216

April 27, 2017

Sponsor: National Cancer Institute (NCI)

Number: Alchemist A151216

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer (Click here for lung cancer staging definitions) that has been, or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Who’s eligible:

Pre-surgical patients must have either:

    • Suspected diagnosis of resectable non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 institutional review board (IRB) approved.
    • Suspected clinical stage of IIIA, II or large IB (defined as size >= 4cm).

Post-surgical patients must have either:

    • Completely resected non-small cell lung cancer; patients with squamous cell carcinoma are eligible only if the registering site has EA5142 IRB approved.
    • Pathologic stage IIIA, II or IB (defined as size >= 4 cm).
  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1. ECOG status is used by your doctor in order to assess how your disease is progressing, assess how the disease effects of your daily living abilities, and determine appropriate treatment and prognosis.
  • Patients must not have received neoadjuvant therapy (chemo- or radio-therapy) for this lung cancer. Neo adjuvant therapy is therapy given pre-surgery.
  • There must be no prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas; a secondary primary lung cancer is considered a concurrent malignancy and would make a patient ineligible for A151216.
  • No patients known to be pregnant or lactating.
  • This study is for patients age 18 and older.

Available at: The Hospital of Central Connecticut, Hartford Hospital, Backus Hospital- Eastern Connecticut Hematology and Oncology.

Cancer Clinical Research Office